Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a <i>RCSD1::ABL2</i> fusion gene-Reference-Cited by-同舟云学术

Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene

Published:2023-10-09 Issue:1 Volume:65 Page:123-127
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zahid Mohammad Faizan¹²,Kainthla Radhika¹²

Affiliation:

1. Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA

2. Malignant Hematology Clinic, Parkland Health and Hospital System, Dallas, TX, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2264428

Reference17 articles.

1. Novel Therapeutic Approaches for Acute Lymphoblastic Leukemia

2. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

3. Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

4. Role of ABL family kinases in cancer: from leukaemia to solid tumours

5. ABL1 fusion genes in hematological malignancies: a review

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Chemotherapy vs. “TKI + immunotherapy” in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene;Annals of Hematology;2024-05-29

3. Antineoplastics;Reactions Weekly;2024-05-04